Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2021 and Highlights Recent Corporate Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Heron Therapeutics (HRTX) PT Lowered to $20 at Cantor Fitzgerald
March 1, 2022 7:22 AM ESTCantor Fitzgerald analyst Brandon Folkes lowered the price target on Heron Therapeutics (NASDAQ: HRTX) to $20.00 (from $26.00) while maintaining a Neutral rating.
... MoreHeron Therapeutics (HRTX) PT Lowered to $13 at Cowen
March 1, 2022 6:54 AM ESTCowen analyst Boris Peaker lowered the price target on Heron Therapeutics (NASDAQ: HRTX) to $13.00 (from $31.00) while maintaining an Outperform rating following disappointing Q4 results.
The analyst commented, "Heron reported disappointing 4Q21 earnings with Zynrelef reaching sales of only $0.8MM (-61% Q/Q). We... More
Heron Therapeutics (HRTX) Tops Q4 EPS by 4c
February 28, 2022 4:28 PM ESTHeron Therapeutics (NASDAQ: HRTX) reported Q4 EPS of ($0.54), $0.04 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $20.66 million versus the consensus estimate of $25.59 million.
For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.
... More